Pfizer had clues its drug could prevent Alzheimer’s. What happened?
The company’s rheumatoid arthritis drug appeared to reduce the risk of getting Alzheimer’s disease by 64 percent. The Washington Post’s Chris Rowland explains why Pfizer did not pursue it.